Contact Us

Phone Number : 86-15209233790

WhatsApp : +8615209233790

Free call

Detail Information

Product Name: Sildenafil Appearance: White Crystalline Powder
CAS No.: 139755-83-2 EINECS No.: 252-082-4
Specification: 99% Molecular Formula: C22H30N6O4S
Molecular Weight: 474.57600 Shelf Life: 2 Years
Test Method: HPLC Storage: Cool Dry Place
High Light:

1.39 g/cm3 male sexual enhancement


Male Sexual Enhancement 99% Sildenafil


139755-83-2 Sildenafil Citrate Powder

Product Description



Le-nutra Top Grade male sexual enhancement 99% CAS 139755-83-2 sildenafil citrate powder



Base information of Product



Product Name Sildenafil
Appearance White crystalline powder
Cas No. 139755-83-2
Active ingredients 99%
Shelf Life 2 years



Introduction of Product


Sildenafil is a white crystalline powder with the molecular formula C22H30N6O4s and a density of 1.39g/cm3. Sildenafil is a drug for erectile dysfunction that was accidentally invented during the development of drugs for cardiovascular diseases. It is commonly known by its trade name Viagra. But Viagra, the generic name for sildenafil in China, is more widely used and influential than its commercial name.



Function and Application of Product


1. Sildenafil is a selective inhibitor of phosphodiesterase (PDE)V, which can enhance the physiological response of penile erection caused by NO release during sexual stimulation. Mainly used for penile erectile dysfunction.

2. In addition to human cavernous smooth muscle, low concentrations of PDE5 were also found in platelets, blood vessels, visceral smooth muscle and skeletal muscle. Sildenafil may enhance antiplatelet aggregation (in vitro), inhibition of platelet thrombosis (in vivo), and peripheral vasodilation by inhibiting PDE5 in these tissues.


1.39g/Cm3 Male Sexual Enhancement 99% CAS 139755-83-2 Sildenafil Citrate Powder 0


The developing history of Sildenafil


Sildenafil be developed by Pfizer, it was first introduced as a 5-phosphodiesterase inhibitor for the treatment of cardiovascular disease. The researchers hope sildenafil will dilate blood vessels and alleviate cardiovascular disease by releasing the biologically active nitric oxide, which relaxes cardiovascular smooth muscle. However, clinical studies have shown that sildenafil is not as effective as expected. As a cardiovascular drug, sildenafil has shown disappointing performance and has not been able to grow into a successful treatment. In April 1991, a clinical trial of sildenafil officially failed, but a side effect reported by subjects caught researchers' attention. The researchers found that patients who had been tested were reluctant to hand over the remaining drugs. When tracked down, the drug was found to improve the patients' sex lives. Sildenafil's effects on the cavernous muscle of the penis were studied with the approval of Pfizer executives, and on March 27, 1998, the FDA approved the product, making it one of Pfizer's best-known products.




You Might Be Into These
Get in touch with us

Enter Your Message